Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3–internal tandem duplications in the QuANTUM-First trial
Richard F. Schlenk(German Cancer Research Center), Harry P. Erba(Michigan Center for Translational Pathology), Po‐Nan Wang(Chang Gung Memorial Hospital), Jörge E. Cortes(Augusta University Health), Antonio Romero-Aguilar(Hospital Universitario Virgen de las Nieves), Arnaud Lesegretain(Daiichi Sankyo (United States)), Alexander E. Perl(University of Pennsylvania), Mikkael A. Sekeres(University of Miami), James Hanyok(Daiichi Sankyo (United States)), Elżbieta Patkowska(Institute for Transfusion Medicine), Yasser Mostafa Kamel(Daiichi Sankyo (United States)), Radovan Vrḫovac(University Hospital Centre Zagreb), Karima Imadalou(Daiichi Sankyo (United States)), Sergio Amadori(Polyclinic Medical Center), Jianxiang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Mark J. Levis(Sidney Kimmel Cancer Center), Hee‐Je Kim(St. Mary's Hospital), Павел Зак(University Hospital Hradec Králové), Hervé Dombret(University of London Institute in Paris), Li Liu(Daiichi Sankyo (United States)), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 7
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k